Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 7686 results

  1. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

    In development [GID-TA11452] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-HST10061] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    Awaiting development [GID-TA11625] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure

    In development [GID-NG10405] Expected publication date: TBC

    NICE guideline
    In development

  5. Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

    In development [GID-TA11557] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484

    Awaiting development [GID-TA11610] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

    In development [GID-HTE10056] Expected publication date: 24 April 2025

    Health technology evaluations
    In development

  8. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Digital support for children and young people with eating disorders:early value assessment

    Awaiting development [GID-HTE10058] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  10. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development [GID-TA10832] Expected publication date: 22 January 2025

    Technology appraisal guidance
    In development

  12. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  13. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  14. Zuranolone for treating severe postnatal depression ID6431

    In development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation

    In development [GID-NG10427] Expected publication date: 04 February 2025

    NICE guideline
    In development